請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/72501
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林晉玄(Ching-Hsuan Lin) | |
dc.contributor.author | Yi-Kai Tseng | en |
dc.contributor.author | 曾奕凱 | zh_TW |
dc.date.accessioned | 2021-06-17T06:59:59Z | - |
dc.date.available | 2024-08-07 | |
dc.date.copyright | 2019-08-07 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-08-02 | |
dc.identifier.citation | 1. Yang, Y.-L., et al., Distribution and antifungal susceptibility of Candida species isolated from different age populations in Taiwan. Medical Mycology, 2006. 44(3): p. 237-242.
2. Hesstvedt, L., et al., The impact of age on risk assessment, therapeutic practice and outcome in candidemia. Infectious Diseases, 2019. 51(6): p. 425-434. 3. Samaranayake, L., et al., Fungal infections associated with HIV infection. Oral Diseases, 2002. 8(s2): p. 151-160. 4. Pappas, P.G., et al., Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2015. 62(4): p. e1-e50. 5. Segal, B.H., et al., Immunotherapy for Fungal Infections. Clinical Infectious Diseases, 2006. 42(4): p. 507-515. 6. Brown, G.D., et al., Hidden Killers: Human Fungal Infections. Science Translational Medicine, 2012. 4(165): p. 165rv13-165rv13. 7. Pfaller, M.A. and D.J. Diekema, Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem. Clinical Microbiology Reviews, 2007. 20(1): p. 133-163. 8. Weinstein, R.A. and S.K. Fridkin, The Changing Face of Fungal Infections in Health Care Settings. Clinical Infectious Diseases, 2005. 41(10): p. 1455-1460. 9. Kullberg, B.J. and A.M. Oude Lashof, Epidemiology of opportunistic invasive mycoses. European Journal of Medical Research, 2002. 7(5): p. 183-191. 10. Weig, M., U. Groß, and F. Mühlschlegel, Clinical aspects and pathogenesis of Candida infection. Trends in Microbiology, 1998. 6(12): p. 468-470. 11. Wisplinghoff, H., et al., Nosocomial Bloodstream Infections in US Hospitals: Analysis of 24,179 Cases from a Prospective Nationwide Surveillance Study. Clinical Infectious Diseases, 2004. 39(3): p. 309-317. 12. Kojic, E.M. and R.O. Darouiche, Candida Infections of Medical Devices. Clinical Microbiology Reviews, 2004. 17(2): p. 255-267. 13. Ramage, G., J.P. Martínez, and J.L. López-Ribot, Candida biofilms on implanted biomaterials: a clinically significant problem. FEMS Yeast Research, 2006. 6(7): p. 979-986. 14. Wey, S.B., et al., Hospital-Acquired Candidemia: The Attributable Mortality and Excess Length of Stay. JAMA Internal Medicine, 1988. 148(12): p. 2642-2645. 15. Wenzel, R.P., Nosocomial Candidemia: Risk Factors and Attributable Mortality. Clinical Infectious Diseases, 1995. 20(6): p. 1531-1534. 16. Pappas, P.G., et al., Guidelines for Treatment of Candidiasis. Clinical Infectious Diseases, 2004. 38(2): p. 161-189. 17. Gudlaugsson, O., et al., Attributable Mortality of Nosocomial Candidemia, Revisited. Clinical Infectious Diseases, 2003. 37(9): p. 1172-1177. 18. Diekema, D., et al., The changing epidemiology of healthcare-associated candidemia over three decades. Diagnostic Microbiology and Infectious Disease, 2012. 73(1): p. 45-48. 19. Colombo, A.L., et al., Epidemiology of Candidemia in Brazil: a Nationwide Sentinel Surveillance of Candidemia in Eleven Medical Centers. Journal of Clinical Microbiology, 2006. 44(8): p. 2816-2823. 20. Pfaller, M.A., et al., Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010–2012). The Journal of Antibiotics, 2015. 68: p. 556. 21. Salehi, M., et al., Epidemiology and outcomes of Candidemia in a referral center in Tehran. Caspian Journal of Internal Medicine, 2019. 10(1): p. 73-79. 22. Bennett, J.E., et al., Mechanism of increased fluconazole Resistance in Candida glabrata during Prophylaxis. Antimicrobial Agents and Chemotherapy, 2004. 48(5): p. 1773-1777. 23. Panackal, A.A., et al., Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. Journal of Clinical Microbiology, 2006. 44(5): p. 1740-1743. 24. Orozco, A.S., et al., Mechanism of fluconazole resistance in Candida krusei. Antimicrobial Agents and Chemotherapy, 1998. 42(10): p. 2645-2649. 25. Lopez-Ribot, J.L., et al., Distinct patterns of gene expression associated with development of fluconazole resistance in serial Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal Candidiasis. Antimicrobial Agents and Chemotherapy, 1998. 42(11): p. 2932-2937. 26. Kelly, S.L., et al., Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol Δ5,6-desaturation. FEBS Letters, 1997. 400(1): p. 80-82. 27. Hsueh, P.-R., et al., Emergence of nosocomial Candidemia at a Teaching Hospital in Taiwan from 1981 to 2000: Increased susceptibility of Candida Species to fluconazole. Microbial Drug Resistance, 2002. 8(4): p. 311-319. 28. Ruan, S.-Y. and P.-R. Hsueh, Invasive Candidiasis: An overview from Taiwan. Journal of the Formosan Medical Association, 2009. 108(6): p. 443-451. 29. Chen, P.-Y., et al., Comparison of epidemiology and treatment outcome of patients with candidemia at a teaching hospital in Northern Taiwan, in 2002 and 2010. Journal of Microbiology, Immunology and Infection, 2014. 47(2): p. 95-103. 30. Hii, I.-M., et al., Changing epidemiology of candidemia in a medical center in middle Taiwan. Journal of Microbiology, Immunology and Infection, 2015. 48(3): p. 306-315. 31. Lo, H.-J., H.-H. Cheng, and T. Hospitals, Distribution of clinical yeasts in Taiwan. Fung Sci, 2005. 20: p. 83-91. 32. Hii, M., et al., Changing epidemiology of candidemia in a medical center in middle Taiwan. Journal of Microbiology, Immunology and Infection, 2015. 48(3): p. 306-315. 33. Zhou, Z.-L., et al., The distribution and drug susceptibilities of clinical Candida species in TSARY 2014. Diagnostic Microbiology and Infectious Disease, 2016. 86(4): p. 399-404. 34. Cheng, M.-F., et al., Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999. Diagnostic Microbiology and Infectious Disease, 2004. 48(1): p. 33-37. 35. Castellani, A., Obsrvations on the fungi found in tropical bronchomycosis. The Lancet, 1912. 179(4610): p. 13-15. 36. Doi, M., et al., Estimation of chromosome number and size by pulsed-field gel electrophoresis (PFGE) in medically important Candida species. Microbiology, 1992. 138(10): p. 2243-2251. 37. Butler, G., et al., Evolution of pathogenicity and sexual reproduction in eight Candida genomes. Nature, 2009. 459(7247): p. 657. 38. Pfaller, M., et al., Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species. Journal of Clinical Microbiology, 2010. 48(5): p. 1592-1599. 39. Kothavade, R.J., et al., Candida tropicalis: its prevalence, pathogenicity and increasing resistance to fluconazole. Journal of Medical Microbiology, 2010. 59(8): p. 873-880. 40. Neppelenbroek, K.H., et al., Identification of Candida species in the clinical laboratory: a review of conventional, commercial, and molecular techniques. Oral Diseases, 2014. 20(4): p. 329-344. 41. Gago, S., et al., Ribosomic DNA intergenic spacer 1 region is useful when identifying Candida parapsilosis spp. complex based on high-resolution melting analysis. Medical Mycology, 2014. 52(5): p. 472-481. 42. Rosenvinge, F.S., et al., Performance of matrix‐assisted laser desorption‐time of flight mass spectrometry for identification of clinical yeast isolates. Mycoses, 2013. 56(3): p. 229-235. 43. Joseph-Horne, T. and D.W. Hollomon, Molecular mechanisms of azole resistance in fungi. FEMS microbiology letters, 1997. 149(2): p. 141-149. 44. Sanglard, D. and F.C. Odds, Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. The Lancet Infectious Diseases, 2002. 2(2): p. 73-85. 45. Negri, M., et al., Examination of potential virulence factors of Candida tropicalis clinical isolates from hospitalized patients. Mycopathologia, 2010. 169(3): p. 175-182. 46. Pam, V.K., et al., Fluconazole susceptibility and ERG11 gene expression in vaginal Candida species isolated from Lagos Nigeria. International Journal of Molecular Epidemiology and Genetics, 2012. 3(1): p. 84. 47. Woods, R., et al., Resistance to polyene antibiotics and correlated sterol changes in two isolates of Candida tropicalis from a patient with an amphotericin B-resistant funguria. Journal of Infectious Diseases, 1974. 129(1): p. 53-58. 48. Drutz, D. and R. Lehrer, Development of amphotericin B-resistant Candida tropicalis in a patient with defective leukocyte function. The American Journal of the Medical Sciences, 1978. 276(1): p. 77-92. 49. Jain, N., F. Hasan, and B.C. Fries, Phenotypic switching in fungi. Current Fungal Infection Reports, 2008. 2(3): p. 180. 50. Alby, K. and R.J. Bennett, Stress-induced phenotypic switching in Candida albicans. Molecular Biology of the Cell, 2009. 20(14): p. 3178-3191. 51. Noble, S.M., B.A. Gianetti, and J.N. Witchley, Candida albicans cell-type switching and functional plasticity in the mammalian host. Nature Reviews Microbiology, 2017. 15(2): p. 96. 52. Lachke, S.A., et al., Phenotypic switching and filamentation in Candida glabrata. Microbiology, 2002. 148(9): p. 2661-2674. 53. Slutsky, B., et al., ' White-opaque transition': a second high-frequency switching system in Candida albicans. Journal of Bacteriology, 1987. 169(1): p. 189-197. 54. Xie, J., et al., N-acetylglucosamine induces white-to-opaque switching and mating in Candida tropicalis, providing new insights into adaptation and fungal sexual evolution. Eukaryotic Cell, 2012. 11(6): p. 773-782. 55. Sanitá, P.V., et al., In vitro evaluation of the enzymatic activity profile of non-albicans Candida species isolated from patients with oral candidiasis with or without diabetes. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2014. 118(1): p. 84-91. 56. Hube, B. and J. Naglik, Candida albicans proteinases: resolving the mystery of a gene family. Microbiology, 2001. 147(8): p. 1997-2005. 57. Ghannoum, M.A., Potential role of phospholipases in virulence and fungal pathogenesis. Clinical Microbiology Reviews, 2000. 13(1): p. 122-143. 58. Favero, D., et al., Production of haemolytic factor by clinical isolates of Candida tropicalis. Mycoses, 2011. 54(6): p. e816-e820. 59. de Melo Riceto, É.B., et al., Enzymatic and hemolytic activity in different Candida species. Revista Iberoamericana de Micología, 2015. 32(2): p. 79-82. 60. Naglik, J.R., et al., Candida albicans HWP1 gene expression and host antibody responses in colonization and disease. Journal of Medical Microbiology, 2006. 55(Pt 10): p. 1323. 61. Phan, Q.T., et al., Als3 is a Candida albicans invasin that binds to cadherins and induces endocytosis by host cells. PLoS Biology, 2007. 5(3): p. e64. 62. Sundstrom, P., E. Balish, and C.M. Allen, Essential role of the Candida albicans transglutaminase substrate, hyphal wall protein 1, in lethal oroesophageal candidiasis in immunodeficient mice. The Journal of infectious diseases, 2002. 185(4): p. 521-530. 63. Naglik, J.R., et al., Candida albicans interactions with epithelial cells and mucosal immunity. Microbes and Infection, 2011. 13(12-13): p. 963-976. 64. De Groot, P.W., et al., The cell wall of the human pathogen Candida glabrata: differential incorporation of novel adhesin-like wall proteins. Eukaryotic Cell, 2008. 7(11): p. 1951-1964. 65. Costa‐de‐Oliveira, S., et al., Determination of chitin content in fungal cell wall: an alternative flow cytometric method. Cytometry Part A, 2013. 83(3): p. 324-328. 66. Davey, M.E. and G.A. O'toole, Microbial biofilms: from ecology to molecular genetics. Microbiol. Mol. Biol. Rev., 2000. 64(4): p. 847-867. 67. Kolter, R. and E.P. Greenberg, The superficial life of microbes. Nature, 2006. 441(7091): p. 300. 68. Fanning, S. and A.P. Mitchell, Fungal biofilms. PLoS Pathogens, 2012. 8(4): p. e1002585. 69. Costerton, J.W., P.S. Stewart, and E.P. Greenberg, Bacterial biofilms: a common cause of persistent infections. Science, 1999. 284(5418): p. 1318-1322. 70. Mah, T.-F.C. and G.A. O'Toole, Mechanisms of biofilm resistance to antimicrobial agents. Trends in Microbiology, 2001. 9(1): p. 34-39. 71. Hall-Stoodley, L., J.W. Costerton, and P. Stoodley, Bacterial biofilms: from the natural environment to infectious diseases. Nature Reviews Microbiology, 2004. 2(2): p. 95. 72. Dominguez, E., et al., Conservation and divergence in the Candida species biofilm matrix mannan-glucan complex structure, function, and genetic control. MBio, 2018. 9(2): p. e00451-18. 73. Donlan, R.M., Biofilm formation: a clinically relevant microbiological process. Clinical Infectious Diseases, 2001. 33(8): p. 1387-1392. 74. Kuhn, D. and M. Ghannoum, Candida biofilms: antifungal resistance and emerging therapeutic options. Current Opinion in Investigational Drugs (London, England: 2000), 2004. 5(2): p. 186-197. 75. Tumbarello, M., et al., Risk factors and outcomes of candidemia caused by biofilm-forming isolates in a tertiary care hospital. PloS One, 2012. 7(3): p. e33705. 76. Pierce, C.G., et al., Antifungal therapy with an emphasis on biofilms. Current Opinion in Pharmacology, 2013. 13(5): p. 726-730. 77. Kornitzer, D., Regulation of Candida albicans hyphal morphogenesis by endogenous signals. Journal of Fungi, 2019. 5(1): p. 21. 78. Biswas, S., P. Van Dijck, and A. Datta, Environmental sensing and signal transduction pathways regulating morphopathogenic determinants of Candida albicans. Microbiol. Mol. Biol. Rev., 2007. 71(2): p. 348-376. 79. Parrino, S.M., et al., cAMP‐independent signal pathways stimulate hyphal morphogenesis in Candida albicans. Molecular Microbiology, 2017. 103(5): p. 764-779. 80. Srinivasa, K., et al., A MAP kinase pathway is implicated in the pseudohyphal induction by hydrogen peroxide in Candica albicans. Molecules and Cells, 2012. 33(2): p. 183-193. 81. Csank, C., et al., Roles of the Candida albicans mitogen-activated protein kinase homolog, Cek1p, in hyphal development and systemic Candidiasis. Infection and Immunity, 1998. 66(6): p. 2713-2721. 82. Davis, D., et al., Candida albicans RIM101 pH response pathway is required for host-pathogen interactions. Infection and Immunity, 2000. 68(10): p. 5953-5959. 83. Li, W. and A.P. Mitchell, Proteolytic activation of Rim1p, a positive regulator of yeast sporulation and invasive growth. Genetics, 1997. 145(1): p. 63-73. 84. Brown Jr, D.H., et al., Filamentous growth of Candida albicans in response to physical environmental cues and its regulation by the unique CZF1 gene. Molecular Microbiology, 1999. 34(4): p. 651-662. 85. Braun, B.R. and A.D. Johnson, Control of filament formation in Candida albicans by the transcriptional repressor TUP1. Science, 1997. 277(5322): p. 105-109. 86. Murad, A.M.A., et al., NRG1 represses yeast–hypha morphogenesis and hypha‐specific gene expression in Candida albicans. The EMBO Journal, 2001. 20(17): p. 4742-4752. 87. Weber, K., B. Schulz, and M. Ruhnke, The quorum‐sensing molecule E, E‐farnesol—its variable secretion and its impact on the growth and metabolism of Candida species. Yeast, 2010. 27(9): p. 727-739. 88. Gulati, M. and C.J. Nobile, Candida albicans biofilms: development, regulation, and molecular mechanisms. Microbes and Infection, 2016. 18(5): p. 310-321. 89. Green, C.B., et al., Construction and real-time RT-PCR validation of Candida albicans PALS-GFP reporter strains and their use in flow cytometry analysis of ALS gene expression in budding and filamenting cells. Microbiology, 2005. 151(4): p. 1051-1060. 90. Li, F., et al., Eap1p, an adhesin that mediates Candida albicans biofilm formation in vitro and in vivo. Eukaryotic Cell, 2007. 6(6): p. 931-939. 91. Nobile, C.J. and A.P. Mitchell, Regulation of cell-surface genes and biofilm formation by the C. albicans transcription factor Bcr1p. Current Biology, 2005. 15(12): p. 1150-1155. 92. Ramage, G., et al., Our current understanding of fungal biofilms. Critical Reviews in Microbiology, 2009. 35(4): p. 340-355. 93. Lebeaux, D., J.-M. Ghigo, and C. Beloin, Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics. Microbiol. Mol. Biol. Rev., 2014. 78(3): p. 510-543. 94. Al-Fattani, M.A. and L.J. Douglas, Biofilm matrix of Candida albicans and Candida tropicalis: chemical composition and role in drug resistance. Journal of Medical Microbiology, 2006. 55(8): p. 999-1008. 95. Nobile, C.J., et al., Biofilm matrix regulation by Candida albicans Zap1. PLoS Biology, 2009. 7(6): p. e1000133. 96. Nett, J.E., et al., Interface of Candida albicans biofilm matrix-associated drug resistance and cell wall integrity regulation. Eukaryotic Cell, 2011. 10(12): p. 1660-1669. 97. Mukherjee, P.K., et al., Alcohol dehydrogenase restricts the ability of the pathogen Candida albicans to form a biofilm on catheter surfaces through an ethanol-based mechanism. Infection and Immunity, 2006. 74(7): p. 3804-3816. 98. Sturtevant, J., et al., Identification and cloning of GCA1, a gene that encodes a cell surface glucoamylase from Candida albicans. Medical Mycology, 1999. 37(5): p. 357-366. 99. Uppuluri, P., et al., Dispersion as an important step in the Candida albicans biofilm developmental cycle. PLoS Pathogens, 2010. 6(3): p. e1000828. 100. Uppuluri, P., et al., The transcriptional regulator Nrg1p controls Candida albicans biofilm formation and dispersion. Eukaryotic Cell, 2010. 9(10): p. 1531-1537. 101. Robbins, N., et al., Hsp90 governs dispersion and drug resistance of fungal biofilms. PLoS Pathogens, 2011. 7(9): p. e1002257. 102. Granger, B.L., Insight into the antiadhesive effect of yeast wall protein 1 of Candida albicans. Eukaryotic Cell, 2012. 11(6): p. 795-805. 103. Uppuluri, P., et al., Candida albicans dispersed cells are developmentally distinct from biofilm and planktonic cells. MBio, 2018. 9(4): p. e01338-18. 104. Nobile, C.J., et al., A recently evolved transcriptional network controls biofilm development in Candida albicans. Cell, 2012. 148(1-2): p. 126-138. 105. Nobile, C.J., et al., Critical role of Bcr1-dependent adhesins in C. albicans biofilm formation in vitro and in vivo. PLoS Pathogens, 2006. 2(7): p. e63. 106. Lohse, M.B., et al., Assessment and optimizations of Candida albicans in vitro biofilm assays. Antimicrobial Agents and Chemotherapy, 2017. 61(5): p. e02749-16. 107. Sherrington, S.L., et al., Adaptation of Candida albicans to environmental pH induces cell wall remodelling and enhances innate immune recognition. PLoS Pathogens, 2017. 13(5): p. e1006403-e1006403. 108. Vylkova, S., et al., The fungal pathogen Candida albicans autoinduces hyphal morphogenesis by raising extracellular pH. MBio, 2011. 2(3): p. e00055-11. 109. Cho, T., et al., In vitro efficacy of continuous mild heat stress on the antifungal susceptibility of Candida albicans biofilm formation. Biological and Pharmaceutical Bulletin, 2012. 35(8): p. 1371-1373. 110. Pumeesat, P., et al., Candida albicans biofilm development under increased temperature. New Microbiol, 2017. 40(3): p. 1-14. 111. Ikezaki, S., et al., Mild heat stress affects on the cell wall structure in Candida albicans biofilm. Medical Mycology Journal, 2019. 60(2): p. 29-37. 112. Philips, J., et al., Biofilm formation by Clostridium ljungdahlii is induced by sodium chloride stress: experimental evaluation and transcriptome analysis. PLoS One, 2017. 12(1): p. e0170406. 113. Tamura, G., et al., Adherence of group B Streptococci to cultured epithelial cells: roles of environmental factors and bacterial surface components. Infection and Immunity, 1994. 62(6): p. 2450-2458. 114. Song, B. and L.G. Leff, Influence of magnesium ions on biofilm formation by Pseudomonas fluorescens. Microbiological Research, 2006. 161(4): p. 355-361. 115. Dass, C.L., et al., Irrigant divalent cation concentrations influence bacterial adhesion. Journal of Surgical Research, 2009. 156(1): p. 57-63. 116. Wu, Y., et al., Multilocus microsatellite markers for molecular typing of Candida tropicalis isolates. BMC Microbiology, 2014. 14(1): p. 245. 117. Taff, H.T., et al., Mechanisms of Candida biofilm drug resistance. Future Microbiology, 2013. 8(10): p. 1325-1337. 118. Mudgil, D., The interaction between insoluble and soluble fiber, in dietary fiber for the prevention of cardiovascular disease. 2017, Elsevier. p. 35-59. 119. Hollomon, J.M., The biology of morphology: insight into regulation of Candida albicans hyphal growth by pH and Cdk8. 2017: Dartmouth College. 120. Buffo, J., M.A. Herman, and D.R. Soll, A characterization of pH-regulated dimorphism in Candida albicans. Mycopathologia, 1984. 85(1-2): p. 21-30. 121. Davis, D., R.B. Wilson, and A.P. Mitchell, RIM101-dependent and-independent pathways govern pH responses in Candida albicans. Molecular and Cellular Biology, 2000. 20(3): p. 971-978. 122. Stoldt, V.R., et al., Efg1p, an essential regulator of morphogenesis of the human pathogen Candida albicans, is a member of a conserved class of bHLH proteins regulating morphogenetic processes in fungi. The EMBO Journal, 1997. 16(8): p. 1982-1991. 123. Mancera, E., et al., Finding a missing gene: EFG1 regulates morphogenesis in Candida tropicalis. G3: Genes, Genomes, Genetics, 2015. 5(5): p. 849-856. 124. McEldowney, S. and M. Fletcher, Variability of the influence of physicochemical factors affecting bacterial adhesion to polystyrene substrata. Appl. Environ. Microbiol., 1986. 52(3): p. 460-465. 125. Brooks, T. and C. Keevil, A simple artificial urine for the growth of urinary pathogens. Letters in Applied Microbiology, 1997. 24(3): p. 203-206. 126. Hermansson, M., The DLVO theory in microbial adhesion. Colloids and Surfaces B: Biointerfaces, 1999. 14(1-4): p. 105-119. 127. Sobeck, D.C. and M.J. Higgins, Examination of three theories for mechanisms of cation-induced bioflocculation. Water Research, 2002. 36(3): p. 527-538. 128. Geesey, G.G., B. Wigglesworth‐Cooksey, and K.E. Cooksey, Influence of calcium and other cations on surface adhesion of bacteria and diatoms: a review. Biofouling, 2000. 15(1-3): p. 195-205. 129. Patrauchan, M.A., et al., Calcium influences cellular and extracellular product formation during biofilm-associated growth of a marine Pseudoalteromonas sp. Microbiology, 2005. 151(9): p. 2885-2897. 130. Somerton, B., et al., Changes in sodium, calcium, and magnesium ion concentrations that inhibit Geobacillus biofilms have no effect on Anoxybacillus flavithermus biofilms. Appl. Environ. Microbiol., 2015. 81(15): p. 5115-5122. 131. Costerton, J.W., Z. Lewandowski, and D.E. Caldwell, Darren R Korber et Hilary M Lappin-scott: Microbial biofilms. Annu. Rev. Microbiol, 1995. 132. Tang, D., et al., Strand-specific RNA-seq analysis of the Acidithiobacillus ferrooxidans transcriptome in response to magnesium stress. Archives of Microbiology, 2018. 200(7): p. 1025-1035. 133. Zaatreh, S., et al., Fast corroding, thin magnesium coating displays antibacterial effects and low cytotoxicity. Biofouling, 2017. 33(4): p. 294-305. 134. Zaatreh, S., et al., Thin magnesium layer confirmed as an antibacterial and biocompatible implant coating in a co‑culture model. Molecular Medicine Reports, 2017. 15(4): p. 1624-1630. 135. Baig, A., Biochemical composition of normal urine. 2011. 136. Tan, L., et al., Antifungal activity of spider venom-derived peptide lycosin-I against Candida tropicalis. Microbiological Research, 2018. 216: p. 120-128. 137. Uppuluri, P., et al., Characteristics of Candida albicans biofilms grown in a synthetic urine medium. Journal of Clinical Microbiology, 2009. 47(12): p. 4078-4083. 138. Fox, E.P., et al., An expanded regulatory network temporally controls Candida albicans biofilm formation. Molecular Microbiology, 2015. 96(6): p. 1226-1239. 139. Alby, K., D. Schaefer, and R.J. Bennett, Homothallic and heterothallic mating in the opportunistic pathogen Candida albicans. Nature, 2009. 460: p. 890. 140. Chen, Y.-C., Investigation of six conserved transcriptional factors on the regulation of hyphal formation and biofilm development in Candida tropicalis. Department of Biochemical Science and Technology College of Life Science. 2017, National Taiwan University. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/72501 | - |
dc.description.abstract | 念珠菌為臨床常見的伺機性感染真菌,在世界各地皆造成嚴重的威脅。由於氣候與環境因素,熱帶念珠菌 (Candida tropicalis) 為臺灣院內感染比例排行第二的念珠菌,僅次於白色念珠菌 (Candida albicans)。然而,臺灣對於熱帶念珠菌相關的研究卻非常缺乏。生物膜的生成對於念珠菌是非常重要的致病因子,同時造成臨床治療的困難。生物膜是微生物群聚成複雜且具有結構性的群落,不僅能提供穩定的生長環境,也能幫助微生物抵抗環璄壓力、藥物或人體免疫系統的作用。臨床統計上顯示,65%院內感染與生物膜生成有關。除了在特定的器官外,也會在一些醫療器材上形成生物膜,例如:人工導管、人工關節以及心律調節器等。在白色念珠菌中,前人的研究發現生物膜的生成主要是由Ndt80、Bcr1、Brg1、Efg1、Rob1與Tec1等轉錄因子組成緊密的調控網絡,調控高達一千多個基因,當其中任何一個基因功能缺失時都會導致白色念珠菌無法產生菌絲或無法貼附,進而影響生物膜生成。實驗室先前將熱帶念珠菌中的這些同源基因剔除並觀察是否有類似性狀,發現大部分的同源基因缺失時也都會導致菌絲無法生成,然而,部分基因缺失反而是促進菌絲生成的現象,說明了兩物種間相關的調控機制有所不同。礙於目前實驗室尚未有一套熱帶念珠菌生物膜培養方法,無法進一步探討熱帶念珠菌這些基因在菌絲生長的差異是否會影響到後續生物膜生成情形。因此,本研究的目的在於發展一套熱帶念珠菌生物膜體外培養的技術,並對此技術進行改良與評估,並利用該方法探討熱帶念珠菌同源基因對於生物膜生成的影響以及詳細的調控機制。實驗結果發現,以合成尿液 (Synthetic urine) 作為養分來源並搭配醫療級矽膠材質作為附著的表面進行培養,能夠有效誘導熱帶念珠菌生物膜生成。透過測試與修正,目前已經發展出一個熱帶念珠菌的生物膜生成的穩定系統。此外,我們發現合成尿液中的鎂離子的存在與熱帶念珠菌生物膜的生成具有重要關聯性,缺乏鎂離子的情況下會使得生物膜生成嚴重受到抑制。最後,我們證實熱帶念珠菌六個同源基因Ndt80、Bcr1、Brg1、Efg1、Rob1與Tec1,皆會正向調控生物膜的生成,當其中的任何一個基因缺失時,都會使得熱帶念珠菌無法有效生成生物膜,然而這六個同源基因對於生物膜生成的影響有程度上的差異,這也代表著熱帶念珠菌與白色念珠菌間的生物膜調控機制可能有所不同。未來,將利用本實驗建立的系統,進一步探討熱帶念珠菌生物膜生成機制,有助於未來發展熱帶念珠菌感染時的治療策略與藥物開發。 | zh_TW |
dc.description.abstract | Candida tropicalis, an opportunistic human fungal pathogen, can cause superficial and systemic infection in immunocompromised patients. In Taiwan, C. albicans remains the most isolated Candida species, but C. tropicalis has become the second most dominant species. However, compared to the study of C. albicans, there are relatively few investigations that focus on C. tropicalis. Consequently, it is critical and more essential to emphasize C. tropicalis while investigating the Candida species in Taiwan. The propensity for causing infection is highly associated with its ability to form biofilms, leading to hampering clinical treatment. Biofilms are complex and structured communities of microorganisms attached to surfaces or host cells. It is a major growth form in natural environments and a leading cause of about 65% clinical microbial infection. The hallmark of biofilms is their remarkable environmental stress tolerance, drug resistance, and immune defense. In C. albicans, six transcription factors, including Bcr1, Brg1, Rob1, Tec1, Efg1 and Ndt80, form a complex regulatory circuit in controlling biofilm formation. Loss of each gene causes biofilm defects dramatically. Our previous studies have speculated the function of six homolous genes in C. tropicalis is somewhat different from C. albicans in hyphal formation. In order to explore more about C. tropicalis biofilm formation mechanism, the biofilm formation assay on silicones was established with some modifications. In particular, replacement of Spider medium with synthetic urine in the adherent step and the developmental stage is necessary to gain better results and more biofilms. Furthermore, we find magnesium in synthetic urine affects C. tropicalis biofilm formation. Lacking magnesium causes biofilm formation deficiency. In C. tropicalis, deletion of BCR1, BRG1, EFG1, TEC1, ROB1 and NDT80, respectively, also caused a significant reduction in biofilm formation from a mild to severe degree. Together, this system for C. tropicalis biofilms will allow us to unveil the molecular mechanisms of action in biofilm formation of the 2nd most fungal pathogen in Taiwan. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T06:59:59Z (GMT). No. of bitstreams: 1 ntu-108-R06b22006-1.pdf: 3616495 bytes, checksum: 3fd30bc3e9e7de4ab59c50c51f4f3de3 (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 目錄 頁碼
中文摘要 I 英文摘要 III 目錄 V 表目錄 VII 圖目錄 VIII 第一章 文獻回顧 1 第一節 念珠菌與造成的臨床威脅 1 第二節 非白色念珠菌念珠菌屬 2 第三節 念珠菌於台灣院內感染盛行率 3 第四節 熱帶念珠菌 (Candida tropicalis) 3 第五節 念珠菌的致病因子 4 第六節 念珠菌菌絲生成機制 7 第七節 念珠菌生物膜特性與生成機制 7 第八節 白色念珠菌生物膜基因調控網絡 9 第二章 實驗目的 11 第三章 材料與方法 12 第一節 實驗材料 12 第二節 實驗方法 13 第四章 實驗結果 15 第一節 不同培養成分與貼附表面對熱帶念珠菌生物膜生成之影響 15 第二節 各種培養條件對熱帶念珠菌生物膜生成效果之影響 16 第三節 生物膜生成程度評估 18 第四節 合成尿液中各成分對於熱帶念珠菌生物膜生成之影響 20 第五節 鎂離子對熱帶念珠菌生物膜生成之影響 21 第六節 CtBcr1、CtBrg1、CtRob1、CtEfg1、CtNdt80以及CtTec1對於熱帶念珠菌生物膜生成之影響 22 第五章 討論 24 第六章 結論 31 第七章 未來研究方向 32 第八章 圖表 33 第九章 參考文獻 54 第十章 附錄 64 | |
dc.language.iso | zh-TW | |
dc.title | 以合成尿液與矽膠材質建立熱帶念珠菌生物膜培養的方法 | zh_TW |
dc.title | Development of Candida tropicalis biofilms on silicones in a synthetic urine medium | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 張麗冠(Li-Kuan Chang),薛雁冰(Yen-Ping Hsueh),吳?承(Hsuan-Chen Wu),黃慶璨(Ching-Tsan Huang) | |
dc.subject.keyword | 熱帶念珠菌,合成尿液,生物膜, | zh_TW |
dc.subject.keyword | Candida tropicalis,synthetic urine,biofilm, | en |
dc.relation.page | 73 | |
dc.identifier.doi | 10.6342/NTU201902392 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2019-08-05 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生化科技學系 | zh_TW |
顯示於系所單位: | 生化科技學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf 目前未授權公開取用 | 3.53 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。